KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

Bibliographic Details
Main Authors: G. Gravis, M. Kolinsky, L. Mourey, J.M. Piulats, S. Sridhar, E. Romano, W. Berry, H. Gurney, M. Retz, L. Appleman, M. Boegemann, J. De Bono, A. Joshua, U. Emmenegger, H. Conter, B. Laguerre, H. Wu, C. Schloss, C. Poehlein, E.Y. Yu
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320331633

Internet

http://www.sciencedirect.com/science/article/pii/S2666168320331633

Similar Items